Visiopharm Announces Akoya Biosciences as an Authorized Reseller of Oncotopix® Discovery and Biotopix™

November 5th, 2018

Visiopharm A/S announced today a partnership with Akoya Biosciences, the technology leader in multiplexed immunofluorescence including the Phenoptics™ portfolio with the Vectra® and Vectra Polaris® systems. As part of this agreement, Akoya becomes an authorized reseller of Visiopharm’s suite of image analysis software, including Phenomap™ and the teach-by-example Artificial Intelligence (AI) modules.

Visiopharm is very pleased to have Akoya Biosciences join our partner and authorized reseller community. Our complementary technologies enable scientists and pathologists to better interrogate the disease biology through biomarker discovery and automated cell phenotyping within tissue samples. Our joint customers will benefit from two companies who are committed to driving innovation and providing solutions that deliver efficiency, standardization, and the reproducibility required to support large scale translational studies from discovery through clinical research” said Amanda Lowe, Senior Vice President of Visiopharm.

Read more

Visiopharm Becomes a Technology Leader in Deep Learning and AI Image Analysis for Digital Pathology

October 3rd, 2018

Visiopharm Launches AI Powered by Deep Learning: Letting Pathologists Harness the Power of AI

The Oncotopix®/Biotopix™ AI image analysis platform is powered by the latest technological breakthroughs in AI and Deep Learning, providing the most comprehensive solution for image analysis available for Digital Pathology today.

With near infinite configurability, the Visiopharm AI software platform addresses even the most complex and challenging image analysis applications. This allows scientists and researchers to grow and evolve with their research without constantly hitting the walls of software limitations.

Read more

Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis

September 10th, 2018

Visiopharm Phenomap software presented at the Fluidigm Imaging Mass Cytometry User Group Meeting, expanding the suite of Hyperion Imaging System data analysis tools for translational and clinical research 

Fluidigm Corporation (NASDAQ:FLDM) and Visiopharm A/S today announced a co-marketing relationship to automate image analysis for Imaging Mass Cytometry™ (IMC™). Under the terms of this agreement, Fluidigm and Visiopharm will cooperatively promote Visiopharm® image analysis software in conjunction with the Fluidigm® Hyperion™ Imaging System, MCD™ Viewer software and related Maxpar® antibodies and kits.

Read more

LAUNCHING Phenomap™ - New Automated Phenotyping Software Tool Streamlined Analysis Workflow of High Dimensional Images

September 7th, 2018

Introducing Visiopharm Phenomap™ Multiplexing a novel software tool to help you streamline and automate the analysis workflow of high dimensional multiplex datasets, for deeper understanding of potential relationships in the tumor microenvironment (TME).

Phenomap™ offers a streamlined and intuitive workflow for simultaneous analysis of up to 255 channels by automatically identifying individual cells and performing cell-based phenotyping in high dimensional multiplex images.

Researchers and scientists have a growing necessity for simultaneous analysis of multiple biomarkers to identify immune cells within the tumor microenvironment (TME). Imaging the tumor microenvironment has inherent problems as there are many different types of immune cells to identify.

Read more